Response to Booster Dose Vaccination Programme
According to the Minister at the Prime Minister's Office and Second Minister of Finance and Economy, the extension is also to allow the government...
The Early Endemic Phase Extended For One Month
The Minister at the Prime Minister's Office and Second Minister of Finance and Economy stated that the Early Endemic Phase under the National COVID-19...
315 Cases Detected Since the Early Endemic Phase Began
The Minister of Health also shared that since the Early Endemic Phase began on the 15th of December 2021, 315 cases have been detected...
National Vaccination Programme, 8 Directive Violations Issued Compound Fines
The Minister of Health also shared on the accomplishments of the National Vaccination Programme as of the 9th of January 2022.
The overall population rate...
44 New Cases, 8 Recovered
44 new COVID-19 cases were confirmed yesterday bringing the total number of cases to 15,678. Yang Berhormat Dato Seri Setia Doctor Haji Awang Mohd...
Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with...
Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announced that the last patient has been dosed with sonlicromanol in the KHENERGYZE Phase IIb clinical […]
MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio
MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV® test recently cleared for use by US FDA to aid in distinguishing between bacterial and viral infection on the point-of-need platform MeMed Key® HAIFA, Israel; BOSTON, MA; January 10th, 2022 – MeMed, a leader in host response technologies, today announces a $93 million […]
Nyxoah Provides General Corporate Update
Nyxoah Provides General Corporate Update Transformational 2021 positions Nyxoah for further clinical, regulatory, and commercial milestones in 2022 Mont-Saint-Guibert, Belgium – January 10, 2022, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep […]